Heron Therapeutics (HRTX) Income from Discontinued Operations (2010 - 2012)

Heron Therapeutics (HRTX) has reported Income from Discontinued Operations for 3 consecutive years, with $1.1 million the latest figure, recorded in Q4 2012.

• For the quarter ending Q4 2012, Income from Discontinued Operations rose 1233.33% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2013 stood at $1.2 million (up 419.62% YoY), and the FY2012 full-year result was $1.1 million, up 385.49% from the prior year.
• Income from Discontinued Operations rose to $1.1 million in Q4 2012 per HRTX's latest filing, from $128000.0 in the prior quarter.
• Across five years, Income from Discontinued Operations topped out at $1.1 million in Q4 2012 and bottomed at -$129000.0 in Q2 2011.
• Historically, Income from Discontinued Operations has averaged $56400.0 across 3 years, with a median of -$71000.0 in 2011.
• The sharpest annual moves came in 2011 and 2012: Income from Discontinued Operations sank 41.67% in 2011, then jumped 1233.33% in 2012.
• Over 3 years, Income from Discontinued Operations stood at -$103000.0 in 2010, then rose by 6.8% to -$96000.0 in 2011, then surged by 1233.33% to $1.1 million in 2012.
• According to Business Quant data, Income from Discontinued Operations over the past three periods registered $1.1 million, $128000.0, and -$43000.0 for Q4 2012, Q3 2012, and Q2 2012 respectively.